Laurie Toich, Assistant Editor

A new merger between Horizon Pharma and Raptor Pharmaceuticals is expected to increase rare disease ventures.

System may improve diagnosis of immunogolbulin E-related conditions.

High-quality hospitals cost Medicare $2700 less within 30 days of a patient’s major surgery.

Altering relaxin-3 could improve symptoms from mental illness.

Lysozyme expression may be an early predictor of Alzheimer’s disease.

Top news of the day from across the healthcare landscape.

Top news of the day from across the health care landscape.

Women, Caucasians, and young adults disproportionally affected by infective endocarditis from injection drug use.

Bill HR 5951 seeks to prevent retroactive fees by Medicare drug plans and pharmacy benefit managers after prescriptions are filled.

A recent analysis may provide states with aspects of healthcare that need improvement.

FDA warns the use of the contaminated eye wash in hospitals and pharmacies could cause a sight-threatening infection.

Overuse of permethrin/synergized pyrethrins has caused resistant head lice.

A healthy body mass index was associated with a higher ischemic stroke risk compared with a high body mass index.

Dexrazoxane may prevent chemotherapy-related heart conditions in children.

Top news of the day from across the healthcare landscape.

Pembrolizumab (Keytruda) was previously granted Breakthrough Therapy Designation for advanced non-small cell lung cancer.

National Association of Specialty Pharmacy notes that providers should focus on delivering high quality care to patients without focusing on high price tags.

Orphan drugs only accounted for 8.9% of total pharmaceutical expenditures in 2013.

A Supplemental Biologics License Application was submitted for Keytruda for the treatment of lung cancer.

Levetiracetam and topirimate may not affect intelligence of children whose mothers took the drug while pregnant.

Fromoterol with budesonide treatment shown to be just as safe and effective as budesonide monotherapy.

Fungi and bacteria in chronic wounds can cause mixed biofilms that prevent healing.

Top news of the day from across the healthcare landscape.

An experimental drug from Pfizer could potentially prevent inhibit drug addiction.

Biogen will discuss results from various studies examining their expansive portfolio of multiple sclerosis drugs.

Roche has been named the most sustainable healthcare company for the eighth time.

Novartis experimental drug BAF312 met its primary endpoints in a phase 3 study.

Prolia found to increase bone mineral density in patients with glucorticoid-induced osteoporosis.

Investigators at ViiV Healthcare are analyzing a 2-drug regimen of dolutegravir and lamivudine for HIV.

Aducanumab shows ability to reduce amyloid plaque levels in an interim analysis of a phase 1b study.